Medical Cannabis in Australia: What is Legal?

Medicinal cannabis can be prescribed in Australia, but legal access depends on the product, the prescriber, and the applicable Commonwealth, state, and territory rules. A prescription does not mean that every product has been approved by the Therapeutic Goods Administration (TGA), and medical access does not authorize recreational sales.

Australia’s 2016 reforms established a framework for licensed cultivation and manufacture for medicinal and scientific purposes. The first commercial cultivation licence was announced in March 2017. Today, the more useful question for patients is which access pathway applies to their proposed treatment.

Registered Medicines and Unapproved Products

The TGA’s patient information identifies Sativex (nabiximols) and Epidyolex (cannabidiol) as registered products. These have been assessed for quality, safety, and efficacy for their approved uses. They do not require a separate TGA special-access approval simply because they contain cannabinoids.

Most other medicinal cannabis products are supplied as unapproved therapeutic goods. “Unapproved” means they are not included in the Australian Register of Therapeutic Goods (ARTG); it does not mean that a valid special-access supply is illegal. It also does not mean the TGA has established that the individual product is effective for every condition for which it is prescribed.

Appropriate clinical assessment, prescribing requirements, and any relevant state or territory permissions still apply. Your usual GP can discuss the options, and nurse practitioners may prescribe within their authority and the applicable rules.

How the Access Pathways Work

For an unapproved product, the prescriber handles the relevant TGA access application or notification. Two common pathways are:

• Special Access Scheme Category B: a patient-specific application supported by a clinical justification, including why registered alternatives are unsuitable.
• Authorised Prescriber scheme: an eligible medical practitioner receives authority to prescribe specified products or categories for defined patient groups, subject to the authorization’s conditions and reporting requirements.

An Authorised Prescriber does not need a fresh individual TGA application for every patient covered by that authority. The scheme is restricted to medical practitioners; nurse practitioners use the pathways available to them. The prescriber must also consider local controlled-medicine rules.

After the requirements are satisfied, the patient takes the prescription to a pharmacy. Confirm availability first: a pharmacy may need to order the medicine, and a prescribed vaping product may require a compatible device that the pharmacy can supply.

THC, CBD, and Product Selection

THC is the cannabinoid most associated with intoxication and impairment. CBD does not produce the same high, but it can still cause adverse effects and interact with medicines. Neither “hemp-derived” nor “full-spectrum” tells you whether a product is suitable for your condition.

The TGA’s product lists organize unapproved products into cannabinoid categories and show information reported by suppliers. They are aids for prescribers and pharmacists, not endorsements of efficacy or guarantees of current pharmacy stock. A list of products supplied during a reporting period should not be presented as a fixed number of approved medicines.

Product form matters too. Oral liquids, capsules, sprays, and inhaled products differ in delivery and timing. Prescribed vaporization exists within the medical system, so it is incorrect to say doctors generally cannot prescribe that route. Smoking cannabis is not a recommended medical delivery method. Follow the product-specific prescription rather than substituting a different route or strength.

What Conditions Can Be Treated?

There is no national list of “40 approved conditions” establishing that cannabis works for all of them. The TGA’s access FAQ explains that it does not restrict the indications for which a practitioner may apply for an unapproved product. An application still needs an adequate clinical rationale; permission to supply is different from proof of therapeutic benefit.

Registered medicines have specific indications. For example, the Australian approval for Epidyolex covers additional treatment of seizures associated with Lennox-Gastaut or Dravet syndrome in patients aged two and older. Sativex is used for specified multiple-sclerosis-related spasticity. These examples should not be generalized to every cannabis formulation or neurological condition.

For other uses, evidence varies by symptom, preparation, and study. Queensland Health’s treatment guidance distinguishes possible symptom management from treatment of the underlying disease and states that medicinal cannabis is not an effective primary treatment for cancer. A broad list including diabetes, Alzheimer’s disease, HIV, and cancer should not imply established effectiveness for treating those diseases.

A practical treatment discussion should cover the symptom being targeted, alternatives already tried, expected benefit, adverse effects, and when treatment will be reviewed or stopped. Do not reduce opioids or other prescribed medicines on your own because cannabis has been added.

Side Effects and Monitoring

The TGA’s patient guidance lists effects including sedation, fatigue, dizziness, nausea, changes in appetite, dry mouth, and diarrhoea. THC-containing products can also cause anxiety, confusion, hallucinations, and other psychiatric effects. Risk depends on the person, medicine, and dose.

CBD’s risks are not limited to rare mild headaches. The Australian product information for Epidyolex includes liver monitoring requirements and important drug-interaction precautions, particularly involving medicines such as valproate. Monitoring for one prescription product should not be replaced with a general claim that CBD is harmless.

Discuss pregnancy or breastfeeding, mental-health history, cardiovascular disease, liver problems, falls risk, and all other medicines with the prescriber. Doses and follow-up need to be individualized. A dose suitable for another patient or another formulation is not a reliable starting point.

Can You Buy CBD Without a Prescription?

A Schedule 3 category for certain low-dose CBD preparations took effect on February 1, 2021. However, the TGA’s current access information states that no ARTG products meet that classification. The existence of a pharmacist-only category does not mean an unregistered CBD oil can be sold over the counter.

Do not equate an overseas wellness website or an Australian online storefront with authorization to supply a medicine. Check the lawful access route for the actual product.

Costs and PBS Coverage

Most unapproved medicinal cannabis treatment is paid for privately, with costs depending on consultations, follow-up, medicine, and any required device. Ask for the total expected cost before starting, including recurring appointments and dispensing.

It is incorrect to say that no cannabinoid medicines receive Pharmaceutical Benefits Scheme support. Epidyolex has PBS listings with authority requirements. Subsidy depends on meeting the applicable restrictions; it does not extend to all CBD products or all uses. A pharmacist or prescriber can check eligibility for the individual prescription.

Driving and Travel

A lawful prescription does not automatically make driving lawful or safe. Healthdirect explains that THC affects driving ability and that CBD can cause drowsiness and fatigue. Roadside drug laws and available defenses differ across jurisdictions, so discuss both impairment and the relevant state or territory law before driving.

Do not rely on feeling sober or on a universal waiting period to establish that THC will no longer be detectable. For travel, check the destination’s medicine rules and documentation requirements before carrying a cannabis medicine across an international border.

How the ACT’s Personal-Use Rules Differ

The Australian Capital Territory’s rules apply within the ACT, not throughout Australia. ACT Policing describes exemptions from criminal liability for adults in specified circumstances, including possession of up to 50 grams of dried cannabis or 150 grams of fresh cannabis and cultivation of up to two plants per person, with four per household.

Public use, sales, gifting or sharing, and artificial cultivation remain prohibited under those rules. Commonwealth law also continues to apply. These provisions are separate from prescription medical access and do not create a recreational dispensary market.

For patients anywhere in Australia, the useful starting point is a qualified prescriber who can explain the evidence, the applicable access pathway, the costs, and a plan to monitor benefit and harm.